Loading...
Receive $200 for creating an Interactive Brokers account using our link: Create IBKR account. Read our Interactive Brokers analysis
- Ticker
- NGNE
- Price
- 17.38
- Stock movement up
- +- (0.00%)
- Company name
- Neurogene Inc
- Exchange
- (NASDAQ ,
- Currency
- USD )
- Sector
- Healthcare >Biotechnology
- Market cap
- 269.21M
- Ent value
- 220.50M
- Price/Sales
- -
- Price/Book
- 1.01
- Div yield
- -
- Div growth
- -
- Growth years
- -
- FCF payout
- -
- Trailing P/E
- -
- Forward P/E
- -
- PEG
- -
- EPS growth
- 10.74%
- 1 year return (CAGR)
- -7.41%
- 3 year return (CAGR)
- 12.18%
- 5 year return (CAGR)
- -42.85%
- 10 year return (CAGR)
- -21.49%
Last updated: 2026-02-19
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
DIVIDENDS
NGNE does not pay dividends or no data was received
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
VALUATION
Valuation Ratios
Loading...
Valuation Ratios data
| Trailing P/E | - |
| Price to OCF | - |
| Price to FCF | - |
| Price to EBITDA | - |
| EV to EBITDA | - |
Valuation (Sales/Book Value)
Loading...
Valuation (Sales/Book Value) data
| Price to Sales | - |
| Price to Book | 1.01 |
| EV to Sales | -238.38 |
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
FINANCIALS
Per share
Loading...
Per share data
| Current share count | 15.49M |
| EPS (TTM) | -4.02 |
| FCF per share (TTM) | -3.71 |
Income statement
Loading...
Income statement data
| Revenue (TTM) | -925.00K |
| Gross profit (TTM) | -16.92M |
| Operating income (TTM) | -97.31M |
| Net income (TTM) | -85.13M |
| EPS (TTM) | -4.02 |
| EPS (1y forward) | -4.58 |
Margins
Loading...
Margins data
| Gross margin (TTM) | 1829.30% |
| Operating margin (TTM) | 10520.00% |
| Profit margin (TTM) | 9203.24% |
Balance Sheet
Loading...
Please create a free account or log in to access this chart
Balance Sheet data
| Cash | 71.00M |
| Net receivables | 860.00K |
| Total current assets | 270.52M |
| Goodwill | 0.00 |
| Intangible assets | 0.00 |
| Property, plant and equipment | 29.34M |
| Total assets | 287.83M |
| Accounts payable | 1.54M |
| Short/Current long term debt | 11.27M |
| Total current liabilities | 14.71M |
| Total liabilities | 22.29M |
| Shareholder's equity | 265.54M |
| Net tangible assets | 0.00 |
Cash flow
Loading...
Please create a free account or log in to access this chart
Cash flow data
| Operating cash flow (TTM) | -77.41M |
| Capital expenditures (TTM) | 1.17M |
| Free cash flow (TTM) | -78.58M |
| Dividends paid (TTM) | 0.00 |
Financial returns
Loading...
Please create a free account or log in to access this chart
Financial returns data
| Return on Equity | -32.06% |
| Return on Assets | -29.58% |
| Return on Invested Capital | -31.61% |
| Cash Return on Invested Capital | -29.18% |
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
STOCK INFORMATION
Stock chart
Loading...
Stock price data
| Open | 17.42 |
| Daily high | 17.71 |
| Daily low | 16.78 |
| Daily Volume | 108K |
| All-time high | 442.60 |
| 1y analyst estimate | 57.20 |
| Beta | 2.04 |
| EPS (TTM) | -4.02 |
| Dividend per share | 0.00 |
| Ex-div date | - |
| Next earnings date | - |
Downside potential
Loading...
Downside potential data
| NGNE | S&P500 | |
| Current price drop from All-time high | -96.07% | -1.82% |
| Highest price drop | -98.34% | -56.47% |
| Date of highest drop | 8 Apr 2025 | 9 Mar 2009 |
| Avg drop from high | -67.09% | -10.84% |
| Avg time to new high | 429 days | 12 days |
| Max time to new high | 2642 days | 1805 days |
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
COMPANY DETAILS
Marketcap
269.21M
Marketcap category
Small-cap
Description
Neurogene Inc., a clinical stage biotechnology company, develops genetic medicines for rare neurological diseases. The company's product candidates include NGN-401 that is packaged in an adeno-associated virus 9, which is in Phase 1/2 clinical trial for the treatment of Rett syndrome; and NGN-101, a conventional gene therapy candidate that is in Phase 1/2 clinical trial to treat CLN5 Batten disease. It has a license agreements with The University of Edinburgh, Virovek, Inc., Sigma-Aldrich Co. LLC., and Leland Stanford Junior University. The company was founded in 2018 and is headquartered in New York, New York.
Employees
107
Website
Investor relations
-
SEC filings
CEO
Country
USA
City
Stock type
-
CCC status
-
Dividend Frequency
-
EVENTS AND PRESENTATIONS
EventsPresentations
Loading...
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
UNDERSTAND THE BUSINESS
Loading...
COMPANY NEWS
Seeking AlphaPress releases
iO Charts is a Seeking Alpha partnerNext page